Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26951416 | 0.89 | MTNR1B (0.64) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL7267986 | 0.88 | MTNR1A (0.63) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL585472 | 0.87 | APLNR (0.56) | MEN1KMT2ARAB9A | |
| SCHEMBL7332981 | 0.87 | HSD17B10 (0.63) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL490458 | 0.86 | HSD17B10 (0.55) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL491188 | 0.85 | HSD17B10 (0.71) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL11077966 | 0.85 | MTNR1A (0.62) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL30436820 | 0.85 | HSD17B10 (0.71) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL7060135 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BHSD17B10ADRA1ATAAR1 | |
| SCHEMBL2968686 | 0.84 | NPC1 (0.60) | MTNR1AMTNR1BMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| WO-2014082381-A1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-7871822-B2 | Method of use for characterizing the catalytic reactivity of catalyst(s) | NOVALYST DISCOVERY (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| US-20070161038-A1 | Method of use for characterizing the catalytic reactivity of catalyst(s) | NOVALYST DISCOVERY (FR) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | MTNR1A 2668/4885MTNR1B 2072/4885HSD17B10 377/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MTNR1A 3414/4885MTNR1B 3549/4885HSD17B10 2123/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | MTNR1A 2295/4885MTNR1B 1752/4885HSD17B10 492/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MTNR1A 3722/4885MTNR1B 4193/4885HSD17B10 1235/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MTNR1A 3414/4885MTNR1B 3549/4885HSD17B10 2123/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | MTNR1A 2295/4885MTNR1B 1752/4885HSD17B10 492/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | MTNR1A 2295/4885MTNR1B 1752/4885HSD17B10 492/4885 |
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | MTNR1A 1124/4885MTNR1B 338/4885HSD17B10 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.